RxDoctor Payments Data

Michael Schiedler, DO

Interventional Cardiology · Salem, ORNPI 1841552692

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,035 of the $1,199 with a category attached, or 86.3%. 10 manufacturers reported payments, led by Abbott at 28.0% of the total. Reporting peaked in 2021 at $736 and has fallen 96.5% since, to $26 in 2025. That places this record below the midpoint for interventional cardiology clinicians in OR, where the typical reported total is $4,729.

$1,199in general payments, 2019–2025

Across 17 payments — averaging $70.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$336
  • Medtronic$330
  • Abiomed$248
  • W. L. Gore & Associates, Inc.$135
  • Philips North America LLC$69
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$1,03586%
  • Education$16514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,199 in reported general payments places this provider in the 20th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$80,788
Medicare patients
750
Services billed
1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$145,464
FarxigaDapagliflozin Propanediol13$19,282
XareltoRivaroxaban16$12,256
Rosuvastatin Calcium190$2,746
Isosorbide Dinitrate19$2,527
Metoprolol Succinate219$2,319
Atorvastatin Calcium120$1,544
Ezetimibe58$1,447
Potassium Chloride58$1,442
Carvedilol111$962
ClopidogrelClopidogrel Bisulfate89$961
Valsartan39$833
Losartan Potassium79$672
Torsemide33$578
Nitroglycerin21$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$145,464111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 68 interventional cardiology providers in Oregon.

Other interventional cardiology in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →